

Syncom Formulations (India) Limited

CIN No.: L24239MH1988PLC047759 A WHO-GMP & ISO 9001-2015 Certified Company

SYNCOM/SE/2018-19

Online Filing at: listing.bseindia.com

14th Nov., 2018

To, The General Manager DCS-CRD BSE Ltd. Rotunda Building P.J. Tower, Dalal Street, Fort, MUMBAI-400001

BSE CODE: 524470

Sub: Submission of the Standalone Un-Audited Financial Results & Limited Review Report for the Quarter/Half Year ended 30th September, 2018 u/r 33 of the SEBI (LODR) Regulations, 2015.

Dear Sir,

This is in continuation of our letter no. SYNCOM/SE/2018-19 dated 30th October, 2018 regarding intimation of Board meeting for consideration and approval of the Quarter/Half Year Standalone Un-Audited Financial Results& Limited Review Report thereon, for the Quarter/Half Year ended 30th September, 2018.

Pursuant to Regulation 33 of SEBI (LODR) Regulation, 2015 we are pleased to submit the following;

(a) Unaudited Financial Results for the Quarter/Half Year 30th September, 2018; and

(b) Limited Review Report by the Auditors for the quarter 30th September, 2018,

Which was considered and approved by the Board at their 04/2018-19 Meeting held on Wednesday, the 14th November, 2018.

The Financial Results will also be published in widely circulated English and Marathi (Vernacular) newspaper in the prescribed format for that purpose.

We are also in process of filing the aforesaid financial results in the XBRL format within the stipulated time and same shall be hosted on the Website of the Company.

You are requested to please take on record the above said Unaudited financial results & Limited Review Report for your reference and record.

Thanking You, Yours Faithfully,

PAYAL MANGAL COMPANY SECRETARY & COMPLIANCE OFFICER Encl: a/a



Bringing a smile on every face...

Regd. Off. : 7, Niraj Industrial Estate, Off Mahakali Caves Road, Andheri (East), MUMBAI - 400093, INDIA, Tel.: +91-22-30887744 - 54, Fax: +91-22-30887755, Email: sfil87@hotmail.com Corp. Off. : 207, Saket Nagar, INDORE - 452 018, INDIA. Tel. : +91-731-2560458 / 2700458, Email : info@sfil.in Works : 256-257, Sector-I, PITHAMPUR, Dist.-Dhar, M.P. - 454 775, INDIA, Tel.: +91-7292-403122 / 407039, Email : info@sfil.in Website : http://www.sfil.in

SYNCOM FORMULATIONS (INDIA) LTD. Regd. Off.: 7, Niraj Industrial Estate, Off Mahakali Caves Road, Andheri (E), MUMBAI - 400 093 Works : 256-257, Sector - 1, Pithampur (Dhar), E-mail : info@sfil.in, CIN : L24239MH1988PLC047759

STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH SEPTEMBER, 2018												
S.	Particulars	-			arter End	r Ended		Half Year Ended		Year End		
No.	(Rs. in Lakhs) (Excep	ot EPS)	30.09.2 (Unaud		30.06.201 (Unaudited				30.09.2017 (Unaudited)	31.03.20 (Audite		
1	Income from Operations			- 00	0004.00	0004	~	7700.07	7004.04	45000		
2	(a) Net sales Other Income		4495	5.28 0.97	3291.69 126.21	3891.		7786.97 247.18	7994.21 182.56	15863. 443.		
3	Total Income		4616		3417.90	4003.		8034.15	8176.77	16307.		
4	Expenses		0000	- 00	0000.04	1769.	0.5	0.00		7700		
	(a) Cost of Material Consumed (b) Purchase of stock in trade		2225	5.29	2086.61			4312.60 987.11	3837.76 1679.57	7760.		
	(c) Changes in inventories of finished goods, Work in prog	gress										
	and stock in trade (d) Employee Benefit Expenses			9.58 5.37	(246.25) 364.83			23.33 750.20		(65.8 1504.		
	(e) Finance Cost			5.01	6.45		56	11.46	11.80	26.		
	(f) Depreciation and amortization Expenses			8.19 6.77	99.39 464.96			197.58 1181.73		372. 2296.		
	(g) Other Expenses Total Expenses (4)		4236		3227.81			7464.01		15095		
5	Profit/ (loss) before exceptional & extraordinary		200	0.05	100.00	000				1011		
6	item and tax (3-4) Exceptional Items			0.05	190.09 0.00		.00	570.14 0.00		1211		
7	Profit /(loss) before extraordinary items & tax (5-6)		380	0.05	190.09	288.	41	570.14	603.12	1201		
8	Tax Expenses (a) Current Tax			0.00	0.00		00	0.00 170.00		0 306		
	(b) Deferred Tax			.00)	(55.00)			(107.00)	20.00	29		
9	Profit/ (loss) for the period from continuing operations (7-8	3)		2.05	205.09			507.14		864		
10 11	Profit/(loss) from discontinuing operations Tax Expenses of discontinuing Operations (after Tax)			0.00	0.00		00	0.00 0.00		0		
12	Profit/ (loss) for the period from Discontinuing operations					and the				100.00		
13	(after Tax) (10-11) Profit/ (loss) for the period (9+12)			0.00 2.05	0.00		66	0.00		0 864		
14	Other Comprehensive Income :											
A	(i) Items that will not be reclassified to P& L	indt	(0.00	0.00	0.	.00	0.00	0.00	0		
	(ii) Income Tax relating to items that will not be reclassifi Profit & Loss	ied to	(0.00	0.00	0	.00	0.00	0.00	0		
В	(i) Items that will be reclassified to P& L			.46)	(28.39)			(43.85)		101		
	(ii) Income tax relating to items that will be reclassified to Profit & Loss		(0.00	0.00	0	.00	0.00	0.00	0		
15	Total comprehensive income for the period (16+17)		· ·	0.00	0.00			0.00	0.00			
	(Comprising Profit/(loss) and other comprehensive Incon	ne for	000		470 70	055	~	100.00	455.00			
16	the period Paid up Share Capital of the Company (Face Value 1/-)		7806	6.59	176.70 7806.52			463.29 7806.52		966 7806		
17	Reserves excluding revaluation reserves		1000	-	1000.01		-	-	-	4387		
18	Earning Per Share (of Rs. 1/- each) for continuing Operati (a) Basic	ons		0.04	0.02	0	.03	0.06	0.06	0		
	(b) Diluted			0.04	0.02		03	0.06		0		
19	Earning Per Share (of Rs. 1/- each) for Dis-contin	nuing										
	Operations (a) Basic		(0.00	0.00	0	.00	0.00	0.00	0		
	(b) Diluted			0.00	0.00		00	0.00	0.00	0		
20	Earning Per Share (of Rs. 1/- each) for Dis-contil Operations and continuing operations	nuing										
	(a) Basic			0.04	0.02		.03	0.06		0		
	(b) Diluted		(0.04	0.02	0.	.03	0.06	0.06	0		
	SEGMENT WISE REVENUE, RES	SUL'	TS A	10	NG WI	TH QU	IAR	TERL	Y RESU	LTS		
				LU	IAO ANI							
	Particulars		Qu	arte	r Ended		_	lalf Year	Ended	Year End		
		30.09.2 (Unaud	Qu 2018	arte 30.00	r Ended	0.09.2017 Jnaudited)	30.0	alf Year				
0.	Particulars	30.09.2	Qu 2018	arte 30.00	r Ended	0.09.2017	30.0	alf Year	Ended 30.09.2017	Year End 31.03.20		
0.	Particulars - (Rs. in Lakhs) Segment Revenue a) Pharmaceuticals Drugs & Formulations	30.09.2 (Unaud	Qu 2018 lited) 20.79	30.06 (Unai	r Ended 5.2018 3 udited) (U 951.47	0.09.2017 Jnaudited) 3777.13	30.0 (Una	alf Year 9 .2018 audited) 7172.26	Ended 30.09.2017 (Unaudited) 6867.29	Year End 31.03.20 (Audite 13690		
0.	Particulars (Rs. in Lakhs) Segment Revenue a) Pharmaceuticals Drugs & Formulations b) Trading of Commodities	30.09.2 (Unaud 422 30	Qu 2018 lited) 20.79 05.51	30.06 (Unai	r Ended 5.2018 3 udited) ((951.47 382.23	0.09.2017 Jnaudited) 3777.13 143.80	30.0 (Una	alf Year 9 .2018 audited) 7172.26 687.74	Ended 30.09.2017 (Unaudited) 6867.29 1173.90	Year End 31.03.20 (Audite 13690 2320		
0.	Particulars - (Rs. in Lakhs) Segment Revenue a) Pharmaceuticals Drugs & Formulations	30.09.2 (Unaud 422 30	Qu 2018 lited) 20.79	30.00 (Unat	r Ended 5.2018 3 udited) (U 951.47	0.09.2017 Jnaudited) 3777.13	30.0 (Una 7	alf Year 9 .2018 audited) 7172.26	Ended 30.09.2017 (Unaudited) 6867.29	Year End 31.03.20 (Audite 13690 2320 295		
0.	Particulars (Rs. in Lakhs) Segment Revenue a) Pharmaceuticals Drugs & Formulations b) Trading of Commodities c) Renting of Property Total Segment Revenue Less: Inter Segment Revenue	30.09.2 (Unaud 422 30 8 461	Qu 2018 lited) 20.79 05.51 39.95 6.25 0.00	29 30.00 (Unai 29 34	r Ended 3.2018 3 udited) ((951.47 382.23 84.20 417.90 0.00	0.09.2017 Jnaudited) 3777.13 143.80 82.32 4003.25 0.00	30.0 (Una 7	Ialf Year 9.2018 audited) 7172.26 687.74 174.15 3034.15 0.00	Ended 30.09.2017 (Unaudited) 6867.29 1173.90 135.58 8176.77 0.00	Year End 31.03.20 (Audite 13690 2320 295 16307 0		
o. 1	Particulars (Rs. in Lakhs) Segment Revenue a) Pharmaceuticals Drugs & Formulations b) Trading of Commodities c) Renting of Property Total Segment Revenue Less: Inter Segment Revenue Revenue from Operations	30.09.2 (Unaud 422 30 8 461	Qu 2018 lited) 20.79 05.51 39.95 16.25	29 30.00 (Unai 29 34	r Ended 3.2018 3. udited) (I 951.47 382.23 84.20 417.90	0.09.2017 Jnaudited) 3777.13 143.80 82.32 4003.25	30.0 (Una 7	Ialf Year 19.2018 audited) 7172.26 687.74 174.15 3034.15	Ended 30.09.2017 (Unaudited) 6867.29 1173.90 135.58 8176.77	Year End 31.03.20 (Audite 13690 2320 295 16307 0		
lo. 1	Particulars (Rs. in Lakhs) Segment Revenue a) Pharmaceuticals Drugs & Formulations b) Trading of Commodities c) Renting of Property Total Segment Revenue Less: Inter Segment Revenue Revenue from Operations Segment Results Profit(+)/Loss(-) before tax and	30.09.2 (Unaud 422 30 8 461	Qu 2018 lited) 20.79 05.51 39.95 6.25 0.00	29 30.00 (Unai 29 34	r Ended 3.2018 3 udited) ((951.47 382.23 84.20 417.90 0.00	0.09.2017 Jnaudited) 3777.13 143.80 82.32 4003.25 0.00	30.0 (Una 7	Ialf Year 9.2018 audited) 7172.26 687.74 174.15 3034.15 0.00	Ended 30.09.2017 (Unaudited) 6867.29 1173.90 135.58 8176.77 0.00	Year End 31.03.20 (Audite 13690 2320 295 16307 0		
o. 1	Particulars (Rs. in Lakhs) Segment Revenue a) Pharmaceuticals Drugs & Formulations b) Trading of Commodities c) Renting of Property Total Segment Revenue Less: Inter Segment Revenue Revenue from Operations Segment Results Profit(+)/Loss(-) before tax and interest from each segment a) Pharmaceuticals Drugs & Formulations	30.09.2 (Unaud 422 30 8 461 461	Qu 2018 lited) 20.79 05.51 39.95 6.25 0.00 6.25	29 30.00 (Unai 29 34	r Ended 3.2018 3 (I 3.2018 3 (I 951.47 382.23 84.20 417.90 0.00 417.90 98.45	0.09.2017 Jnaudited) 3777.13 143.80 82.32 4003.25 0.00 4003.25 201.02	30.0 (Una 7	lalf Year 19.2018 10.0018 1172.26 687.74 174.15 0034.15 0.00 1034.15 407.55	Ended 30.09.2017 (Unaudited) 6867.29 1173.90 135.58 8176.77 0.00 8176.77 391.54	Year End 31.03.20 (Audite 13690 2320 295 16307 0 16307 820		
o. 1	Particulars (Rs. in Lakhs) Segment Revenue a) Pharmaceuticals Drugs & Formulations b) Trading of Commodities c) Renting of Property Total Segment Revenue Less: Inter Segment Revenue Revenue from Operations Segment Results Profit(+)/Loss(-) before tax and interest from each segment a) Pharmaceuticals Drugs & Formulations b) Trading of Commodities	30.09.2 (Unaud 422 30 8 461 461 30	Qu 2018 lited) 20.79 05.51 39.95 6.25 0.00 6.25 0.00 6.25	29 30.00 (Unai 29 34	r Ended 3.2018 3 Judited) ((951.47 382.23 84.20 417.90 98.45 13.90	0.09.2017 Jnaudited) 3777.13 143.80 82.32 4003.25 0.00 4003.25 201.02 13.37	30.0 (Una 7	lalf Year 19.2018 10172.26 687.74 174.15 0034.15 0.00 1034.15 0.00 0034.15	Ended 30.09.2017 (Unaudited) 6867.29 1173.90 135.58 8176.77 0.00 8176.77 391.54 89.53	Year End 31.03.2((Audite 13690 2320 295 16307 0 16307 820 122		
o. 1	Particulars (Rs. in Lakhs) Segment Revenue a) Pharmaceuticals Drugs & Formulations b) Trading of Commodities c) Renting of Property Total Segment Revenue Less: Inter Segment Revenue Revenue from Operations Segment Results Profit(+)/Loss(-) before tax and interest from each segment a) Pharmaceuticals Drugs & Formulations	30.09.2 (Unaud 422 30 8 461 461 30 8	Qu 2018 lited) 20.79 05.51 39.95 6.25 0.00 6.25 0.00 6.25 0.00 9.10 9.15 39.95	arte 30.00 (Unat 22 34 34	r Ended 3.2018 3 Judited) ((951.47 382.23 84.20 417.90 98.45 13.90 84.20	0.09.2017 Jnaudited) 3777.13 143.80 82.32 4003.25 0.00 4003.25 201.02 13.37 80.58	30.0 (Una 7	lalf Year 9.2018 audited) '172.26 687.74 174.15 0034.15 0.00 1034.15 407.55 23.05 174.15	Ended 30.09.2017 (Unaudited) 6867.29 1173.90 135.58 8176.77 0.00 8176.77 391.54 89.53 133.85	Year End 31.03.2((Audite 13690 2320 295 16307 0 16307 820 122 295		
o. 1	Particulars (Rs. in Lakhs) Segment Revenue a) Pharmaceuticals Drugs & Formulations b) Trading of Commodities c) Renting of Property Total Segment Revenue Less: Inter Segment Revenue Revenue from Operations Segment Results Profit(+)/Loss(-) before tax and interest from each segment a) Pharmaceuticals Drugs & Formulations b) Trading of Commodities c) Renting of Property Total Profit before tax Less: i) Interest	30.09.2 (Unaud 422 30 8 461 461 30 8	Qu 2018 lited) 20.79 05.51 39.95 6.25 0.00 6.25 0.00 6.25	arte 30.00 (Unat 22 34 34	r Ended 3.2018 3 Judited) ((951.47 382.23 84.20 417.90 98.45 13.90	0.09.2017 Jnaudited) 3777.13 143.80 82.32 4003.25 0.00 4003.25 201.02 13.37	30.0 (Una 7	lalf Year 19.2018 10172.26 687.74 174.15 0034.15 0.00 1034.15 0.00 0034.15	Ended 30.09.2017 (Unaudited) 6867.29 1173.90 135.58 8176.77 0.00 8176.77 391.54 89.53	Year End 31.03.2((Audite 13690 2320 295 16307 0 16307 0 16307 820 122 295 1238		
o. 1	Particulars (Rs. in Lakhs) Segment Revenue a) Pharmaceuticals Drugs & Formulations b) Trading of Commodities c) Renting of Property Total Segment Revenue Less: Inter Segment Revenue Revenue from Operations Segment Results Profit(+)/Loss(-) before tax and interest from each segment a) Pharmaceuticals Drugs & Formulations b) Trading of Commodities c) Renting of Property Total Profit before tax Less: i) Interest i) Other Un-allocable Expenditure	30.09.2 (Unaud 422 30 8 461 461 30 8 38	Qu 2018 [lited] 20.79 05.51 39.95 6 6.25 0.00 16.25 0.00 16.25 0.00 55.00	arte 30.00 (Unat 29 34 34 34	r Ended 5.2018 3 .udited) (t 951.47 382.23 84.20 417.90 0.00 417.90 98.45 13.90 84.20 13.90 94.20 6.46	0.09.2017 Jnaudited) 3777.13 143.80 82.32 4003.25 0.00 4003.25 201.02 13.37 80.58 294.97 6.56	30.0 (Una 7	lalf Year 9.2018 10	Ended 30.09.2017 (Unaudited) 6867.29 1173.90 135.58 8176.77 0.00 8176.77 391.54 89.53 133.85 614.92 11.80	Year Enc 31.03.20 (Audite 13690 2320 295 16307 0 16307 820 122 295 1238 6 26 6 26 10		
o. 1	Particulars (Rs. in Lakhs) Segment Revenue a) Pharmaceuticals Drugs & Formulations b) Trading of Commodities c) Renting of Property Total Segment Revenue Less: Inter Segment Revenue Revenue from Operations Segment Results Profit(+)/Loss(-) before tax and interest from each segment a) Pharmaceuticals Drugs & Formulations b) Trading of Commodities c) Renting of Property Total Profit before tax Less: i) Interest ii) Other Un-allocable Expenditure Profit before tax	30.09.2 (Unaud 422 30 8 461 461 30 8 38	Qu 2018 lited) 20.79 05.51 39.95 6.25 0.00 6.25 0.00 6.25 0.00 9.10 9.15 39.95 39.95	arte 30.00 (Unat 29 34 34 34	r Ended 3.2018 3: Judited) ((951.47 382.23 84.20 117.90 0.00 98.45 13.90 98.45 13.90 15	0.09.2017 Jnaudited) 3777.13 143.80 82.32 4003.25 0.00 4003.25 201.02 13.37 80.58 294.97	30.0 (Una 7	lalf Year 19.2018 19.2018 19.2018 19.2018 172.26 687.74 174.15 0034.15 0034.15 0034.15 23.05 174.15 581.60	Ended 30.09.2017 (Unaudited) 6867.29 1173.90 135.58 8176.77 0.00 8176.77 391.54 89.53 133.85 614.92	Year Enc 31.03.20 (Audite 13690 2320 295 16307 0 16307 820 122 295 1238 6 26 6 26 10		
0. 1 2	Particulars (Rs. in Lakhs) Segment Revenue a) Pharmaceuticals Drugs & Formulations b) Trading of Commodities c) Renting of Property Total Segment Revenue Less: Inter Segment Revenue Revenue from Operations Segment Results Profit(+)/Loss(-) before tax and interest from each segment a) Pharmaceuticals Drugs & Formulations b) Trading of Commodities c) Renting of Property Total Profit before tax Less: i) Interest ii) Other Un-allocable Expenditure Profit before tax Gsegment Asset-Segment Liabilities) Segment Asset	30.09.2 (Unaud 422 33 36 461 461 36 8 38 38 38 38	Qu 2018 20.79 35.51 39.95 66.25 0.00 6.25 0.00 9.10 9.15 39.95 5.00 30.05	arte 30.00 (Unat 29 34 34 34	r Ended 5.2018 3 .udited) (t 951.47 382.23 84.20 417.90 0.00 417.90 98.45 13.90 84.20 13.90 94.20 6.46	0.09.2017 Jnaudited) 3777.13 143.80 82.32 4003.25 0.00 4003.25 201.02 13.37 80.58 294.97 6.56	30.0 (Una 7	lalf Year 9.2018 10	Ended 30.09.2017 (Unaudited) 6867.29 1173.90 135.58 8176.77 0.00 8176.77 391.54 89.53 133.85 614.92 11.80	Year End 31.03.20		
lo. 1 2	Particulars (Rs. in Lakhs) Segment Revenue a) Pharmaceuticals Drugs & Formulations b) Trading of Commodities c) Renting of Property Total Segment Revenue Less: Inter Segment Revenue Revenue from Operations Segment Results Profit(+)/Loss(-) before tax and interest from each segment a) Pharmaceuticals Drugs & Formulations b) Trading of Commodities c) Renting of Property Total Profit before tax Less: i) Interest ii) Other Un-allocable Expenditure Profit before tax (Segment Asset a) Pharmaceuticals Drugs & Fomulations	30.09.20 (Unaud 4222 33 36 461 461 30 8 38 38 38 38 38 38 38 38 38 38 38 38 3	Qu 2018 20.79 55.51 99.95 6.25 0.00 9.15 99.95 5.00 80.05 5.00 80.05	29 30.00 (Unau 29 34 34 34	r Ended 3.2018 3.	0.09.2017 Jnaudited) 3777.13 143.80 82.32 4003.25 0.00 4003.25 201.02 13.37 80.58 294.97 6.56 288.41 14129.32	30.(Una 77	lalf Year 19.2018 19.2018 19.2018 19.2018 17.2.26 687.74 174.15 0034.15 0.00 1034.15 23.05 23.05 23.05 581.60 11.46 570.14 2034.67	Ended 30.09.2017 (Unaudited) 6867.29 1173.90 135.58 8176.77 0.00 8176.77 391.54 89.53 133.85 614.92 11.80 603.12 14129.32	Year Enc 31.03.20 (Audite 13690 295 16307 0 16307 820 122 2955 1238 26 10 1201		
0. 1 2	Particulars (Rs. in Lakhs) Segment Revenue a) Pharmaceuticals Drugs & Formulations b) Trading of Commodities c) Renting of Property Total Segment Revenue Less: Inter Segment Revenue Revenue from Operations Segment Results Profit(+)/Loss(-) before tax and interest from each segment a) Pharmaceuticals Drugs & Formulations b) Trading of Commodities c) Renting of Property Total Profit before tax Less: i) Interest ii) Other Un-allocable Expenditure Profit before tax Lessent Asset a) Pharmaceuticals Drugs & Formulations	30.09.2 (Unaud 422 30 2 30 461 461 30 8 8 38 38 38 38 38 38 38 38 38 38 38 38	Qu 2018 20.79 20.79 55.51 39.95 66.25 0.00 9.15 99.10 9.15 99.95 55.00 30.05 5.00	arte 30.00 (Unau 29 34 34 34	r Ended 5.2018 3 Julited) (l 951.47 382.23 84.20 117.90 0.00 117.90 98.45 13.90 84.20 13.90 98.45 13.90 98.420 13.90 98.420 13.90 99.055 6.46 99.09 934.47 934.47 103.45	0.09.2017 Jnaudited) 3777.13 143.80 82.32 4003.25 0.00 4003.25 201.02 13.37 80.58 294.57 6.56 288.41 14129.32 198.43	30.(Una 77 8 8 8 8 8	lalf Year 9.2018 19.2018 19.2018 19.2018 17.2.26 687.74 174.15 0.00 10.34.15 0.00 10.4.15 0.00 10.4.15 174.15 23.05 174.15 581.60 11.46 570.14 20.34.67 19.3.66	Ended 30.09.2017 (Unaudited) 6867.29 1173.90 135.58 8176.77 0.00 8176.77 391.54 89.53 133.85 614.92 11.80 603.12 14129.32 198.43	Year End 31.03.20 (Audite 13690 2320 295 16307 0 16307 820 122 295 1238 26 10 1201 12590 373		
0. 1 2	Particulars (Rs. in Lakhs) Segment Revenue a) Pharmaceuticals Drugs & Formulations b) Trading of Commodities c) Renting of Property Total Segment Revenue Less: Inter Segment Revenue Revenue from Operations Segment Results Profit(+)/Loss(-) before tax and interest from each segment a) Pharmaceuticals Drugs & Formulations b) Trading of Commodities c) Renting of Property Total Profit before tax Less: i) Interest ii) Other Un-allocable Expenditure Profit before tax (Segment Asset a) Pharmaceuticals Drugs & Fomulations	30.09.2 (Unaud 422 30 2 30 8 461 461 30 30 8 38 38 38 38 38 38 38 38 38 38 38 38 3	Qu 2018 20.79 55.51 99.95 6.25 0.00 9.15 99.95 5.00 80.05 5.00 80.05	arte 30.00 (Unat 22 34 34 34 34 34 4119	r Ended 3.2018 3.	0.09.2017 Jnaudited) 3777.13 143.80 82.32 4003.25 0.00 4003.25 201.02 13.37 80.58 294.97 6.56 288.41 14129.32	30.(Una 77 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	lalf Year 9.2018 19.2018 19.2018 19.2018 19.2018 174.15 1034.15 0.00 1034.15 23.05 174.15 581.60 11.46 570.14 2034.67 193.66 1032.02	Ended 30.09.2017 (Unaudited) 6867.29 1173.90 135.58 8176.77 0.00 8176.77 391.54 89.53 133.85 614.92 11.80 603.12 14129.32 198.43 2985.02	Year End 31.03.21 (Audite 13690 2320 295 16307 0 16307 820 122 295 1238 266 10 1201 12590 373 4132		
lo. 1 2	Particulars (Rs. in Lakhs) Segment Revenue a) Pharmaceuticals Drugs & Formulations b) Trading of Commodities c) Renting of Property Total Segment Revenue Less: Inter Segment Revenue Revenue from Operations Segment Results Profit(+)/Loss(-) before tax and interest from each segment a) Pharmaceuticals Drugs & Formulations b) Trading of Commodities c) Renting of Property Total Profit before tax Less: i) Interest ii) Other Un-allocable Expenditure Profit before tax Less: i) Interest a) Pharmaceuticals Drugs & Fomulations b) Trading of Commodities c) Renting of Property Total Segment Asset a) Pharmaceuticals Drugs & Fomulations b) Trading of Commodities c) Renting of Property Total Segment Asset a) Pharmaceuticals Drugs & Fomulations b) Trading of Property Total Segment Asset un-allocable Assets	30.09.2 (Unaud 422 302 8 461 461 30 8 38 38 38 38 38 38 38 38 38 38 38 38 3	Qu 2018 (ited) 20.79 55.51 99.95 6.25 0.00 99.10 99.15 99.95 5.00 30.05 5.00 30.05 5.00 30.05 5.00 30.05 5.00 30.05 5.00	arte 30.00 (Unat 29 3 3 3 4 119 119 40 160	r Ended 3.2018 3.	0.09.2017 Jnaudited) 3777.13 143.80 82.32 4003.25 0.000 4003.25 201.02 13.37 80.58 294.97 6.56 288.41 14129.32 198.43 2985.02 17312.77 0.00	30.(C (Una 7 7 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	lalf Year 19.2018 19.2018 19.2018 19.2018 17.2.26 687.74 174.15 0034.15 0034.15 581.60 11.46 570.14 2034.67 193.66 1032.02 2260.35 0.00	Ended 30.09.2017 (Unaudited) 6867.29 1173.90 135.58 8176.77 0.00 8176.77 391.54 89.53 133.85 614.92 11.80 603.12 14129.32 198.43 2985.02 17312.77 0.00	Year End 31.03.20 (Audite 13690 295 16307 0 16307 16307 820 12295 1238 26 10 1201 12590 373 4132 17096 0 0		
lo. 1 2	Particulars (Rs. in Lakhs) Segment Revenue a) Pharmaceuticals Drugs & Formulations b) Trading of Commodities c) Renting of Property Total Segment Revenue Less: Inter Segment Revenue Revenue from Operations Segment Results Profit(+)/Loss(-) before tax and interest from each segment a) Pharmaceuticals Drugs & Formulations b) Trading of Commodities c) Renting of Property Total Profit before tax Less: i) Interest ii) Other Un-allocable Expenditure Profit before tax (Segment Asset a) Pharmaceuticals Drugs & Fomulations b) Trading of Commodities c) Renting of Property Total Profit before tax Less: i) Interest ii) Other Un-allocable Expenditure Profit before tax Segment Asset a) Pharmaceuticals Drugs & Fomulations b) Trading of Commodities c) Renting of Property Total Segment Asset Un-allocable Assets Un-allocable Assets	30.09.2 (Unaud 422 302 8 461 461 30 8 38 38 38 38 38 38 38 38 38 38 38 38 3	Qu 2018 (itied) 20.79 95.51 39.95 66.25 0.00 66.25 5.00 99.10 9.15 39.95 5.05 5.00 80.05 44.67 33.66 52.02 60.35	arte 30.00 (Unat 29 3 3 3 4 119 119 40 160	r Ended 3.2018 3	0.09.2017 Jnaudited) 3777.13 143.80 82.32 4003.25 0.00 4003.25 201.02 13.37 80.58 294.97 6.56 288.41 14129.32 198.43 2985.02 17312.77	30.(C (Una 7 7 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	lalf Year 9.2018 wdited) (172.26 687.74 174.15 0034.15 0.00 0034.15 23.05 174.15 581.60 11.46 570.14 9034.67 193.66 1032.02 260.35	Ended 30.09.2017 (Unaudited) 6867.29 1173.90 135.58 8176.77 0.00 8176.77 391.54 89.53 133.85 614.92 11.80 603.12 14129.32 198.43 2985.02 17312.77	Year End 31.03.20 (Audite 13690 295 16307 0 16307 16307 820 12295 1238 26 10 1201 12590 373 4132 17096 0 0		
lo. 1 2	Particulars (Rs. in Lakhs) Segment Revenue a) Pharmaceuticals Drugs & Formulations b) Trading of Commodities c) Renting of Property Total Segment Revenue Less: Inter Segment Revenue Revenue from Operations Segment Results Profit(+)/Loss(-) before tax and interest from each segment a) Pharmaceuticals Drugs & Formulations b) Trading of Commodities c) Renting of Property Total Profit before tax Less: i) Interest ii) Other Un-allocable Expenditure Profit before tax (Segment Asset a) Pharmaceuticals Drugs & Fomulations b) Trading of Commodities c) Renting of Property Total Profit before tax Less: i) Interest a) Pharmaceuticals Drugs & Fomulations b) Trading of Commodities c) Renting of Property Total Segment Asset un-allocable Assets Warding of Property Total Segment Asset Segment Liabilities	30.09.2 (Unaud 422 30 8 461 461 30 8 38 38 38 1203 15 403 1626 1626	Qu 2018 20.79 55.51 99.95 66.25 0.00 9.15 99.10 9.15 99.95 55.00 80.05 5.00 80.05 44.67 133.66 12.02 0.035	1119 4(16(16(r Ended 3.2018 3. Jdited) (l 951.47 382.23 84.20	0.09.2017 Jnaudited) 3777.13 143.80 82.32 4003.25 0.00 4003.25 201.02 13.37 80.58 294.97 6.56 288.41 14129.32 198.43 2985.02 17312.77 0.00 17312.77	30.C (Una 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	lalf Year 9.2018 19.2018 19.2018 19.2018 19.2018 17.2.26 687.74 174.15 0.00 034.15 0.00 034.15 23.05 174.15 581.60 11.46 570.14 2034.67 193.66 1032.02 2260.35 0.00 2260.35	Ended 30.09.2017 (Unaudited) 6867.29 1173.90 135.58 8176.77 0.00 8176.77 391.54 89.53 133.85 614.92 11.80 603.12 14129.32 198.43 2985.02 17312.77 0.00 17312.77	Year End 31.03.20 (Audite 13690 295 16307 0 16307 820 122 2955 1238 266 10 1201 12590 373 4132 17096 0 17096		
lo. 1 2	Particulars (Rs. in Lakhs) Segment Revenue a) Pharmaceuticals Drugs & Formulations b) Trading of Commodities c) Renting of Property Total Segment Revenue Less: Inter Segment Revenue Revenue from Operations Segment Results Profit(+)/Loss(-) before tax and interest from each segment a) Pharmaceuticals Drugs & Formulations b) Trading of Commodities c) Renting of Property Total Profit before tax Less: i) Interest ii) Other Un-allocable Expenditure Profit before tax Segment Asset c) Renting of Property Total Profit before tax Less: i) Interest ii) Other Un-allocable Expenditure Profit before tax (Segment Asset c) Renting of Commodities c) Renting of Commodities c) Renting of Property Total Segment Asset Un-allocable Assets Net Segment Asset Segment Liabilities a) Pharmaceuticals Drugs & Fomulations b) Trading of Commodities c) Renting of Commodities d)	30.09.2 (Unaud 422 30 8 461 461 30 8 8 38 38 1203 19 403 1626 1626 344	Qu 2018 (ited) 20.79 55.51 99.95 6.25 0.00 99.10 99.15 99.95 5.00 30.05 5.00 30.05 5.00 30.05 5.00 30.05 5.00 30.05 5.00	1119 4(16(16(r Ended 3.2018 3.	0.09.2017 Jnaudited) 3777.13 143.80 82.32 4003.25 0.000 4003.25 201.02 13.37 80.58 294.97 6.56 288.41 14129.32 198.43 2985.02 17312.77 0.00	30.C (Una 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	lalf Year 19.2018 19.2018 19.2018 19.2018 17.2.26 687.74 174.15 0034.15 0034.15 581.60 11.46 570.14 2034.67 193.66 1032.02 2260.35 0.00	Ended 30.09.2017 (Unaudited) 6867.29 1173.90 135.58 8176.77 0.00 8176.77 391.54 89.53 133.85 614.92 11.80 603.12 14129.32 198.43 2985.02 17312.77 0.00	Year End 31.03.20 (Audite 13690 2320 295 16307 0 16307 820 122 295 1238 266 10 1201 12590 373 4132 17096 0 17096		
lo. 1 2	Particulars (Rs. in Lakhs) Segment Revenue a) Pharmaceuticals Drugs & Formulations b) Trading of Commodities c) Renting of Property Total Segment Revenue Less: Inter Segment Revenue Revenue from Operations Segment Results Profit(+)/Loss(-) before tax and interest from each segment a) Pharmaceuticals Drugs & Formulations b) Trading of Commodities c) Renting of Property Total Profit before tax Less: i) Interest ii) Other Un-allocable Expenditure Profit before tax Less: i) Interest a) Pharmaceuticals Drugs & Fomulations b) Trading of Commodities c) Renting of Property Total Segment Asset a) Pharmaceuticals Drugs & Fomulations b) Trading of Property Total Segment Asset Un-allocable Assets Net Segment Asset Segment Liabilities Segment Liabilities a) Pharmaceuticals Drugs & Fomulations b) Trading of Commodities c) Renting of Property Total Segment Asset Segment Liabilities <td>30.09.2 (Unaud 422 302 8 461 461 30 8 38 38 38 38 1203 1626 1626 344 3 34 3 403 1626 344 3 34 3</td> <td>Qu 2018 (ited) 20.79 55.51 99.95 66.25 0.00 99.10 99.15 39.95 55.00 30.05 55.00 30.05 55.00 30.05 5.00 30.05 6.88 44.67 33.66 20.35 0.00 0.03 5 0.00 5 5.00 34.67 33.66 20.5 5 5.00 34.67 33.66 20.5 5 34.67 33.66 20.5 5 35.00 35.55 35.5</td> <td>arte 30.00 (Unat 29 34 34 34 34 119 119 119 160 33</td> <td>r Ended 3.2018 3. </td> <td>0.09.2017 Jnaudited) 3777.13 143.80 82.32 4003.25 0.00 4003.25 201.02 13.37 80.58 294.97 6.56 288.41 14129.32 198.43 2985.02 17312.77 0.00 17312.77 5204.02 134.10 119.63</td> <td>30.0 (Una 7 7 12 4 16 3</td> <td>lalf Year 19.2018 19.2018 19.2018 19.2018 17.2.26 687.74 174.15 0034.15 23.05 174.15 581.60 11.46 570.14 2034.67 193.66 193.66 193.66 193.66 1032.02 260.35 0.00 1260.35 0.00 1260.35 121.66</td> <td>Ended 30.09.2017 (Unaudited) 6867.29 1173.90 135.58 8176.77 0.00 8176.77 391.54 89.53 133.85 614.92 11.80 603.12 14129.32 198.43 2985.02 17312.77 0.00 17312.77 5204.02 134.10 119.63</td> <td>Year Enc 31.03.20 (Audite 13690 2320 295 16307 0 16307 820 122 295 1238 26 10 1201 12590 373 4132 17096 4636 153 113</td>	30.09.2 (Unaud 422 302 8 461 461 30 8 38 38 38 38 1203 1626 1626 344 3 34 3 403 1626 344 3 34 3	Qu 2018 (ited) 20.79 55.51 99.95 66.25 0.00 99.10 99.15 39.95 55.00 30.05 55.00 30.05 55.00 30.05 5.00 30.05 6.88 44.67 33.66 20.35 0.00 0.03 5 0.00 5 5.00 34.67 33.66 20.5 5 5.00 34.67 33.66 20.5 5 34.67 33.66 20.5 5 35.00 35.55 35.5	arte 30.00 (Unat 29 34 34 34 34 119 119 119 160 33	r Ended 3.2018 3.	0.09.2017 Jnaudited) 3777.13 143.80 82.32 4003.25 0.00 4003.25 201.02 13.37 80.58 294.97 6.56 288.41 14129.32 198.43 2985.02 17312.77 0.00 17312.77 5204.02 134.10 119.63	30.0 (Una 7 7 12 4 16 3	lalf Year 19.2018 19.2018 19.2018 19.2018 17.2.26 687.74 174.15 0034.15 23.05 174.15 581.60 11.46 570.14 2034.67 193.66 193.66 193.66 193.66 1032.02 260.35 0.00 1260.35 0.00 1260.35 121.66	Ended 30.09.2017 (Unaudited) 6867.29 1173.90 135.58 8176.77 0.00 8176.77 391.54 89.53 133.85 614.92 11.80 603.12 14129.32 198.43 2985.02 17312.77 0.00 17312.77 5204.02 134.10 119.63	Year Enc 31.03.20 (Audite 13690 2320 295 16307 0 16307 820 122 295 1238 26 10 1201 12590 373 4132 17096 4636 153 113		
S. lo. 1 2 3	Particulars (Rs. in Lakhs) Segment Revenue a) Pharmaceuticals Drugs & Formulations b) Trading of Commodities c) Renting of Property Total Segment Revenue Less: Inter Segment Revenue Revenue from Operations Segment Results Profit(+)/Loss(-) before tax and interest from each segment a) Pharmaceuticals Drugs & Formulations b) Trading of Commodities c) Renting of Property Total Profit before tax Less: i) Interest ii) Other Un-allocable Expenditure Profit before tax Segment Asset c) Renting of Property Total Profit before tax Less: i) Interest ii) Other Un-allocable Expenditure Profit before tax (Segment Asset c) Renting of Commodities c) Renting of Commodities c) Renting of Property Total Segment Asset Un-allocable Assets Net Segment Asset Segment Liabilities a) Pharmaceuticals Drugs & Fomulations b) Trading of Commodities c) Renting of Commodities d)	30.09.2 (Unaud 422 302 8 461 461 30 8 38 38 38 38 1203 1626 1626 344 3 34 3 403 1626 344 3 34 3	Quu 2018 (itied) 20.79 95.51 99.95 66.25 0.00 16.25 99.10 9.15 5.00 99.10 9.15 5.00 80.05 80.05 80.05 80.05 94.67 93.66 82.02 90.00 90.35 90.000	arte 30.00 (Unat 29 34 34 34 34 119 119 119 160 33	r Ended 3.2018 3 Julited) ((951.47 382.23 84.20 117.90 98.45 13.90 90.09 90.09 90.00 90	0.09.2017 Jnaudited) 3777.13 143.80 82.32 4003.25 0.00 4003.25 201.02 13.37 80.58 294.97 6.56 288.41 14129.32 198.43 2985.02 17312.77 0.00 17312.77 5204.02 134.10	30.0 (Una 7 7 12 4 16 3	lalf Year 9.2018 10	Ended 30.09.2017 (Unaudited) 6867.29 1173.90 135.58 8176.77 0.00 8176.77 391.54 89.53 133.85 614.92 11.80 603.12 14129.32 198.43 2985.02 17312.77 0.00 17312.77 5204.02 134.10	Year Enc 31.03.20 (Audite 13690 2320 295 16307 0 16307 820 1222 295 1238 26 10 1201		

-



Regd. Off.: 7, Niraj Industrial Estate, Off Mahakali Caves Road, Andheri (E), MUMBAI - 400 093 Works : 256-257, Sector - 1, Pithampur (Dhar), E-mail : info@sfil.in, CIN : L24239MH1988PLC047759

STATEMENT OF ASSETS & LIABILITY AS AT 30/09/2018								
	Particulars	AS AT 30.09.2018	AS AT 31.03.2018					
	(Rs. in Lakhs)	(Unaudited)	(Audited)					
A	ASSETS							
	1. Non-current assets							
	(a) Property Plant & Equipment	4826.87	5740.98					
	(b) Capital work in progress	62.85	64.21					
	(c) Investment Property	4020.43	3140.85					
	(d) Goodwill	0.00	0.00					
	(e) Other Intangible Assets	12.37	13.78					
Contra 1	(f) Intangible Asset Under Development	0.00	0.00					
	(g) Biological Assets Other Than Bearer Plants	0.00	0.00					
	(h) Financial Assets	0.00	0.00					
	(i) Investments	155.22	204.18					
	(ii) Trade Receivable	0.00	0.00					
	(iii) Loans	0.00	0.00					
1	(iv) Others (to be specified)	376.16	36.21					
	(i) Deferred tax assets (net)	0.00	0.00					
	(j) Other non-current assets	110.82	59.48					
	2. Current assets	0.00	0.00					
	(a) Inventories	1059.09	1103.66					
	(b) Financial Assets	0.00	0.00					
	(i) Investments	0.00	0.00					
	(ii) Trade receivables	3575.91	3770.05					
		34.08	76.01					
	(iii) Cash and cash equivalents (iv) Bank balances other than (iii) above	626.45	550.87					
	(v) Loans	88.81	124.80					
	(v) Others (to be specified)	0.00	397.00					
		0.00	0.00					
	(c) Current tax assets (Net) (d) Other current assets	1311.29	1814.79					
	Total -Assets	16260.35	17096.87					
в	EQUITY AND LIABILITIES	10200.33	17090.07					
•								
	Equity (a) Equity Share capital	7806.52	7806.52					
	(b) Other Equity	4851.03	4387.73					
	LIABILITIES	4001.00	4307.73					
	(I) Non-current liabilities							
	(a) Financial Liabilities	0.00	0.00					
	(i) Borrowings							
	(ii) Trade payables	0.00	0.00					
	(a) Total outstanding dues of micro enterprises and small	0.00	0.00					
	enterprises and	0.00	0.00					
1.5	(b) Total outstanding dues of creditors other than micro	0.00	0.00					
	enterprises and small enterprises.	0.00	0.00					
	(iii) Other financial liabilities (other than those specified in)	121.66	121.74					
	(b) Provisions	72.97	69.35					
	(c) Deferred tax liabilities (net)	638.63	745.63					
	(d) Other non-current liabilities	0.00	0.00					
	(ii) Current liabilities							
	(a) Financial Liabilities	704.04	F 1011.00					
	(I) Borrowings	734.24	1244.60					
	(ii) Trade payables							
	(a) Total outstanding dues of micro enterprises and small							
	enterprises and	34.36	61.32					
	(b) Total outstanding dues of creditors other than micro							
	enterprises and small enterprises.	1672.03	2169.18					
	(iii) Other financial liabilities (other than those specified in)	20.84	20.76					
1	(b) Other current liabilities	74.17	319.35					
	(c) Provisions	233.90	150.69					
	(d) Current Tax Liabilities (Net)	0.00	0.00					
10.00	TÓTAL - EQUITY AND LIABILITIES	16260.35	17096.87					

Note :-

1. The above results were reviewed by the Audit Committee and thereafter have been adopted by the Board at its meeting held on 14th November, 2018 and the Statutary Auditor of the company have also carried out Limited Review of the Unaudited Results for the Quarter and Half Year ended on 30.09.2018.

2. The above financial results are prepared in compliance with Indian Accounting Standards ("IND-AS") as notified under Section 133 of the Companies Act, 2013 ("the Act") [Companies (Indian Accounting Standards) Rules, 2015] as amended and accordingly these financial results have been prepared in accordance with the recognition and measurement principals let down in the IND AS 34 "Interim Financial Reporting" prescribed u/s 133 of the Companies Act, 2013 read with relevant rules issued there under.

3. The Company is operating in three segments i.e. (a) Pharmaceuticals Drugs & Formulations (b) Trading of commodities and (c) Renting of property, particulars for segment wise results are as above.

4. As required under Regulation 33 of SEBI (LODR) Regulation, 2015 the Limited Review by the Statutory Auditors have been completed for the quarter and half year ended on 30th Sept., 2018. The report does not have any impact on the above results and notes which needs explanations.

5. Previous period figures have been regrouped/reclassified wherever necessary to confirm to this period classification.

6. Excise duty on sales was included under Revenue from operations and disclosed separately under Expenses up to all reporting periods ending 30th June2017. However, after implementation of Goods and Service Tax (GST) from 1st July, 2017, this is no longer relevant.

7. IND AS 115 "Revenue from contract with customers" is mandatory for reporting periods beginning on or after April 5 2018 and replaces the existing revenue recognition requirements. Based on management assessment, the adoption of the standard tid not have any material impact to the financial results of the company. By order of The Board of Directors

For Syncom Formulations (India) Ltd. Kedarmal Bankda

Chairman & Wholetime Director

DIN 00023050

Place : Indore Dated : 14/11/2018

SANJAY MEHTA & ASSOCIATES Chartered Accountants

338, Saket Nagar, Indore - 452 018 Phone/Telefax : 0731-4274391, 2563625 E-mail:sanjaymehta.associates@gmail.com

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS SYNCOM FORMULATIONS (INDIA) LTD.

 We have reviewed the accompanying Statement of Unaudited Financial Results of Syncom Formulations (India) Limited ("the Company"), for the Quarter ended September 30, 2018 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

This statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 Interim Financial Reporting" ("IND AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue report on the Statement based on our review.

- 2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, '*Review of Interim Financial Information performed by the Independent Auditor of the Entity*, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- 3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles' generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, as notified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or it contains any material misstatement.

PLACE: INDORE DATE: 14TH November, 2018

CHARTERED ACCOUNTANTS FRN No. 011524C INDORE

FOR, SANJAY MEHTA & ASSOCIATES

Manish Mittal (PARTNER) M.No. 079452